As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Eli Lilly and Co.’s end last year to its PI3Kα inhibitor program didn’t mean the pharma player was giving up on the target – ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

The 90 million euros ($94 million) raised by Orbis Medicines in a series A round was not January’s biggest venture investment ...

The week's investing action plan includes a strong dose of pharma and biotech earnings, January econ reports, plus Amazon and ...

The integration of AI in healthcare as a means by which to enhance diagnostic accuracy and treatment planning also appeared ...

Bio-Techne (TECH) closed up more than +3% after reporting Q2 ... Squibb Co (BMY), Camden Property Trust (CPT), CMS Energy Corp (CMS), ConocoPhillips (COP), Eli Lilly & Co (LLY), Equifax Inc (EFX), ...

The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...

Vijay Pande, PhD, founding investor of Andreessen Horowitz's Bio + Health fund and a general partner with the tech venture capital firm , discusses how AI’s uptake in healthcare will shape its ...

January jobs data is due on Friday. Plus, earnings from AMD, Alphabet, Chipotle, PayPal, Disney, Eli Lilly, Qualcomm, Amazon, ...

Aktis Oncology, an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for ...